Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Masatoshi Kudo
Abstract
the PD-1/PD-L1 pathway have a limited impact because they do not produce the synergistic inhibitory effects on VEGF-A or WNT/-catenin mutation that are obtained with combination therapy using an ICI plus an anti-VEGF antibody or TKIs.
Topics & Concepts
Hepatocellular carcinomaPD-L1MedicineOncologyInternal medicineImmunotherapyCancerHepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology Research